In late 2022, Teva api completed a $23 million investment in Debrecen, Hungary, with the aim to expand its capability to supply active pharmaceutical ingredients for vital medicines needed for organ transplant patients. This new extraction facility is based in Teva’s Center of Excellence for Fermentation Products, and has been in existence for over 100
Category: Industry updates
The India Situation Room – Managing it all during COVID
As the pandemic broke out globally, emergency response teams sprung up everywhere — and Teva api was no different.
Teva Awarded an EcoVadis 2020 Silver Medal in Recognition of our Sustainability Rating
At Teva api, we are dedicated to leveraging our corporate resources and expertise to promote healthy communities all over the world. Our ambitious, wide-ranging Environment, Social and Governance (ESG) activities and our commitment to sustainability has just won us the 2020 EcoVadis Silver medal, reflecting our ongoing efforts to cultivate responsible business practices and positive
GMP audits reports during COVID-19 times
Completing a Good Manufacturing Practices (GMP) audit report prior to 2020 was simple. Companies had many ways to get theirs done, and a large percentage opted for performing their own onsite audits at their suppliers’ facilities, and then putting together the report themselves. This year however, with travel so limited, this option is difficult if
Our operational presence in Europe and how COVID-19 has changed the playing field
Here at Teva api, we’ve had a significant operational presence in Europe for many years. Over the last few months, as COVID-19 spread relentlessly across the world, we’ve gained a deeper understanding of just how valuable this presence is, and how we could optimize it to best support our supply network and ultimately provide better
Regulations in Brazil are Changing
On April 1st, 2020, Brazil’s ANVISA published new landmark regulations referring to active pharmaceutical ingredients (APIs). This new set of rules consists of three separate guidelines for local pharmaceutical segment stakeholders, known as “RDCs”. These are RDC 359/2020, RDC 361/2020 and RDC 362/2020, and they represent a complete overhaul of the API regulatory landscape in
FCE Brazil 2018 Summary by Teva api
We would like to thank you for taking the time to visit our booth at FCE Pharma 2018. We’ve prepered a short video to conclude the wonderful moments and memories from this years’ FCE. This year our team focused on 2 main benefits of working with Teva api: Teva api’s customer journey – It was a
Teva Appoints John Nason President, Teva api and Biologics Operations
Teva announced the appointment of John Nason to President, Teva Active Pharmaceutical Ingredients (Teva api), a role in which he leads the company’s vertically integrated business unit responsible for the development, manufacture, marketing and sales of bulk API for both third-party manufacturers and for Teva. Mr. Nason also assumes responsibility for the company’s biologics operations, which play an important